ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) a biotechnology firm with a focus on development of next-gen immunotherapies using cell- and gene-based therapies to treat cancer patients posted its financial report for the fourth quarter closed 31, 2017, and issued an update on the firm’s recent activities.
Laurence Cooper, M.D., Ph.D., the Chief Executive Officer of Ziopharm, reported that it is a thrilling year for Ziopharm and the clinical advancement of their two platform technologies, Sleeping Beauty and Controlled IL-12. With Sleeping Beauty, they recorded key milestones last year and are looking forward to what lies ahead in 2018.
They intend to move their point-of-care know-how into the clinic. The CEO of Ziopharm added that they plan to infuse subjects with T cells genetically changed and made without virus utilizing the Sleeping Beauty platform within 2 days from harvesting the T-cells from patients. In addition, Sleeping-Beauty-changed T-cell receptors for neoantigens, the mutations that result in solid tumors, will move into the clinical stage with Dr. Steven Rosenberg’s team.
Dr. Cooper added that with Controlled IL-12, besides assessing this cytokine as a monotherapy, they look forward to upcoming data from their first combination of an immune checkpoint inhibitor and IL-12, and assessing its impact on the care alternatives for the treatment of people with brain cancer. They consider Controlled IL-12 marks as a powerful platform with the prospect for broad applicability across oncology.
Ziopharm is developing Ad-RTS-hIL-12 together with veledimex as a gene treatment product candidate to cure patients with rGBM. Ad-RTS-hIL-12 marks as an adenoviral vector dosed through a single injection straight into the tumor and developed to conditionally express human IL-12. The expression of hIL-12 is modulated and controlled with the RTS® by the small molecule veledimex.
In the last trading session, the stock price of Ziopharm declined more than 2% to close the day at $3.62.